Market Overview

The Law Offices of Howard G. Smith Reminds Investors of July 30th Deadline in the Class Action Lawsuit Against Recro Pharma, Inc. (REPH)


Law Offices of Howard G. Smith reminds investors of the July 30,
deadline to file a lead plaintiff motion in the class action
filed on behalf of investors that purchased Recro Pharma, Inc. ("Recro
Pharma" or the "Company") (NASDAQ: REPH)
securities between July 31, 2017, and May 23, 2018, inclusive
(the "Class Period"). Recro Pharma investors have until July 30,
to file a lead plaintiff motion.

Investors suffering losses on their Recro Pharma investments are
encouraged to contact the Law Offices of Howard G. Smith to discuss
their legal rights in this class action at 888-638-4847 or by email to

On May 24, 2018, Recro Pharma announced that it received a Complete
Response Letter ("CRL") from the U.S. Food and Drug Administration
("FDA") regarding the Company's New Drug Application ("NDA") for IV
meloxicam. In the CRL, the FDA informed the Company that the FDA was
"unable to approve the application in its current form" because "data
from ad hoc analyses and selective secondary endpoints suggest that the
analgesic effect does not meet the expectations of the FDA" and "the CRL
raised CMC related questions on extractable and leachable data provided
in the NDA." On this news, Recro Pharma's share price fell $6.79 per
share, or 54.7%, to close at $5.63 per share on May 24, 2018, thereby
injuring investors.

If you purchased shares of Recro Pharma during the Class Period you may
move the Court no later than July 30, 2018 to ask the
Court to appoint you as lead plaintiff. To be a member of the Class you
need not take any action at this time; you may retain counsel of your
choice or take no action and remain an absent member of the Class. If
you wish to learn more about this action, or if you have any questions
concerning this announcement or your rights or interests with respect to
these matters, please contact Howard G. Smith, Esquire, of Law Offices
of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania
19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by
email to,
or visit our website at

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View Comments and Join the Discussion!